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Breast cancer consists of highly heterogeneous tumors, whose cell of origin and driver
oncogenes are difficult to be uniquely defined. Here we report that MYC acts as tumor
reprogramming factor in mammary epithelial cells by inducing an alternative epigenetic
program, which triggers loss of cell identity and activation of oncogenic pathways. Over-
expression of MYC induces transcriptional repression of lineage-specifying transcription
factors, causing decommissioning of luminal-specific enhancers. MYC-driven dedifferentia-
tion supports the onset of a stem cell-like state by inducing the activation of de novo
enhancers, which drive the transcriptional activation of oncogenic pathways. Furthermore, we
demonstrate that the MYC-driven epigenetic reprogramming favors the formation and
maintenance of tumor-initiating cells endowed with metastatic capacity. This study supports
the notion that MYC-driven tumor initiation relies on cell reprogramming, which is mediated
by the activation of MYC-dependent oncogenic enhancers, thus establishing a therapeutic
rational for treating basal-like breast cancers.
DOI: 10.1038/s41467-018-03264-2 OPEN
1 Laboratory of Chromatin Biology & Epigenetics, Center for Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy. 2 Fondazione Istituto
Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi”, Via F. Sforza 35, 20122 Milan, Italy. 3 Division of Pathology, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milan 20122, Italy. 4 Department of Pathophysiology and Transplantation, University of Milan, Milan 20122, Italy.
5 Dipartimento di Biotecnologie Mediche e Medicina Legale Sezione di Biochimica Medica, Facoltà di Medicina e Chirurgia, Policlinico “P.Giaccone”,
Università di Palermo, Palermo 90127, Italy. 6 Center for Genome Research, University of Modena and Reggio Emilia, Modena 41125, Italy. 7 DiBiMIS,
University of Palermo, Palermo 90127, Italy. These authors contributed equally: Vittoria Poli, Luca Fagnocchi. These authors jointly supervised this work:
Matilde Todaro, Alessio Zippo. Correspondence and requests for materials should be addressed to A.Z. (email: alessio.zippo@unitn.it)
NATURE COMMUNICATIONS |  (2018) 9:1024 | DOI: 10.1038/s41467-018-03264-2 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Tumorigenesis can be ascribed to a succession of genetic andepigenetic alterations that turn in heritable changes in geneexpression programs, ultimately leading to the formation
of a cell population characterized by functional and phenotypic
heterogeneity1,2. Cell transformation frequently involves activa-
tion of developmental signaling programs, which endow cells
with unlimited self-renewal potential and aberrant differentiation
capability3. Somatic stem cells have been considered putative
candidates for targets of transformation because of their inherent
self-renewing capacity and their longevity, which would allow the
acquisition of the combination of genetic and epigenetic aberra-
tions sufficient for cell transformation4. Nevertheless, recent
studies demonstrated that, upon oncogenic alterations, progeni-
tors or committed cells can serve as tumor-initiating cells (TICs)
by dedifferentiating and re-acquiring stem cell-like traits5–7. In
the context of mammary gland tumorigenesis, it has been
demonstrated that the BRCA1 basal-like breast cancer subtype
may arise from luminal progenitor cells8,9. More recently, it has
been shown that expression of oncogenic PIK3CAH1047R in
oncogene-driven normal lineage-restricted mouse mammary cells
causes cell dedifferentiation and development of multi-lineage
mammary tumors10,11. Although these findings highlighted a
functional role for oncogene-driven cell dedifferentiation in
tumor initiation, the molecular mechanisms underlying cell
reprogramming are incompletely understood.
Cell reprogramming requires overcoming those epigenetic
barriers that are involved in maintaining cell-specific transcrip-
tional programs, thereby preserving cell identity12–14. The acti-
vation of a specific repertoire of cis-regulatory elements—
enhancers—is critical for cell specification. Cooperative binding
of lineage-determining (LDTF) and signal-dependent (SDTF)
transcription factors dictates the spatio-temporal pattern of gene
expression15. Enhancers are characterized by accessible chroma-
tin, marked by the deposition of H3K4me1, and their activation is
associated with an increment of H3K27 acetylation16. Given their
pivotal role in the determination of cell identity, decommission-
ing of active enhancers represents a critical step towards cell
reprogramming17. Of importance, evidence indicates that dis-
regulation of chromatin players responsible for enhancer reg-
ulation could favor tumorigenesis by driving the aberrant acti-
vation of oncogenic transcriptional programs18–22.
Among the transcription factors (TFs) with a documented
function in somatic cell reprogramming23, the proto-oncogene
MYC has a pivotal role in growth control, differentiation, and
apoptosis and its expression level is tightly regulated in physio-
logical conditions24. In breast cancer, MYC deregulation has been
associated with up to 40% of tumors, and its hyper activation is a
hallmark of the basal-like subtype24–26. Despite MYC proven
oncogenic potential and its known function in the maintenance of
self-renewing capacity and pluripotency27,28, a causal link
between MYC role as reprogramming factor and its tumorigenic
effects has not been investigated.
Here we demonstrate that MYC acts as an oncogenic repro-
gramming factor by inducing cell plasticity that predisposes
mammary luminal epithelial cells to acquire basal/stem cell-like
properties and to onset of tumorigenesis, giving rise to TICs
endowed with long-term tumorigenic capacity and metastatic
potential.
Results
MYC alters luminal epithelial cell identity. In order to evaluate
the role of MYC in perturbing cell identity of somatic cells, we
transduced hTERT-immortalized human mammary epithelial
cells (thereafter named IMEC) with a retroviral vector expressing
low levels of the exogenous c-Myc (Fig. 1a). MYC overexpression
induced alteration of the epithelial morphology with cells loosing
polarity and adhesion, growing in semi-adherent condition and
forming spheroids (Fig. 1b). Importantly, upon MYC over-
expression we observed a similar phenotype in the luminal breast
cancer cell lines MCF7, T47D, and ZR751 (Supplementary Fig. 1
a, b). Of note, the observed phenotype could not solely rely on
induction of EMT, as we did not detect induction of EMT-related
TFs (Supplementary Fig. 1c). In addition, the modest level of
MYC overexpression did not cause major changes in the cell cycle
profile or timing of cell division in IMEC-MYC (Supplementary
Fig. 1d, e).
Gene expression profiling showed that IMEC-WT and IMEC-
MYC differ for the expression of a specific subset of genes
(Supplementary Fig. 1f) whose regulations was not affected by
global transcriptional amplification, as they showed equivalent
total RNA/cell content and similar cell size (Supplementary
Fig. 1g, h)29,30. Gene ontology (GO) analyses indicated that
IMEC-MYC upregulated genes involved in metabolic processes
and, at the same time, downregulated genes controlling develop-
mental processes, cell adhesion, and extracellular matrix integrity
(Supplementary Fig. 1i)24.
To determine whether MYC-induced alterations at both the
morphological and transcriptional level may trigger perturbation
of cell identity, we compared the gene expression profile of IMEC
WT and -MYC with gene expression signatures of mature (ML)
and progenitor luminal (LP) cells. Gene set enrichment analysis
(GSEA) revealed a marked downregulation of the ML program in
cells overexpressing MYC, combined with a significant enrich-
ment of the LP-specific signature (Fig. 1c and Supplementary
Fig. 1j, k). Of importance, overexpression of MYC in luminal
breast cancer cell lines also caused downregulation of ML-specific
genes (Supplementary Fig. 2a). Hence, MYC overexpression in
mammary luminal cells causes dedifferentiation towards a
progenitor-like state.
MYC downregulates the expression of ML-specific TFs. On the
basis of these results, we asked whether the expression of lineage-
specific transcription factors (LSTFs) was perturbed in con-
sequence of MYC overexpression. We found that IMEC-MYC
downregulated ML-specific TFs while they did not show a global
and consistent modulation of the expression level of LP-specific
regulators (Fig. 1d)31–33. Importantly, genes whose expression is
dependent on luminal-specific TFs binding on their cognate
enhancers34 were downregulated in IMEC-MYC (Fig. 1e). We
therefore focused on GATA3 and ESR1 TFs, two master reg-
ulators of mammary gland morphogenesis and luminal cell dif-
ferentiation35,36. We confirmed that their transcriptional
downregulation was not restricted to IMEC (Fig. 1f) as the same
pattern was induced by MYC overexpression in different luminal
breast cancer cell lines (Supplementary Fig. 2b). Moreover,
knocking-down the exogenous MYC was sufficient to revert the
observed down-modulation of these master regulators of mam-
mary epithelial cells (Supplementary Fig. 2c, e). We then asked
whether GATA3 and ESR1 downregulation could be mediated by
MYC binding to their cis-regulatory elements. Upon MYC
overexpression, we measured a concomitant increase of MYC
association and reduction of active histone marks on GATA3 and
ESR1 regulatory elements (Fig. 1g). Considering that often MYC
deregulation causes transcription repression of its targets by
antagonizing the transcriptional activity of MIZ137,38, we deter-
mined whether the MYC-dependent downregulation of GATA3
and ESR1 could be mediated by MIZ1 binding. ChIP assay
showed that MIZ1 associated on the analyzed cis-regulatory ele-
ments (Fig. 1g) and its knock-down reverted the MYC-driven
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Fig. 1 MYC inhibits the transcriptional program of mature luminal epithelial cells. a Western blot of c-MYC in IMEC WT and IMEC-MYC; β-ACTIN was
used as loading control. Signal quantification is reported. Data are means ± SEM (n= 3). (**P < 0.01; Student’s t-test). b Phase contrast images of confluent
IMECWT and IMEC-MYC. Scale bar, 200 µm. c GSEA of mature luminal (ML) and luminal progenitor (LP) gene signatures in IMECWT vs. IMEC-MYC (n
= 3). d Heatmap showing the expression of luminal specifying TFs in IMECWT and IMEC-MYC. e GSEA of genes regulated by enhancers bound by mature
luminal-specific TFs in IMEC WT vs. IMEC-MYC (n= 3). f qRT-PCR of GATA3 and ESR1 in IMEC WT and IMEC-MYC, normalized on spike-in RNAs. Data
are means ± SEM (n= 3). (**P < 0.01, ***P < 0.001; Student’s t-test). g ChIP-qPCR assessing MYC and MIZ1 binding and H3K4me3, H3K27ac, and
H3K4me1 deposition at GATA3 promoter and ESR1 intronic enhancer in IMEC WT and IMEC-MYC. A scheme showing GATA3 and ESR1 PCR amplicons
localization (red boxes) and layered H3K27ac signals from ENCODE is represented. Data are means ± SEM (n= 3). h Box plots representing the protein
levels of GATA3 (left panel) and ESR1 (right panel) in breast cancer samples with unaltered or altered MYC level. i Scheme showing the MYC-induced
reprogramming of IMEC WT to the luminal progenitor-like state of IMEC-MYC
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Fig. 2 Sustained MYC overexpression confers stem cell-like traits. a Phase contrast images of IMEC WT and IMEC-MYC cultured in low adhesion
conditions. Scale bar, 100 µm. b Spheres formation efficiency (SFE) of IMEC WT and IMEC-MYC at indicated passages (n= 6) (**P < 0.01, ***P < 0.001;
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transcription repression of GATA3 and ESR1 (Supplementary
Fig. 2f, g).
To establish the pathological relevance of the anti-correlation
between MYC overexpression and ESR1/GATA3 downregulation,
we assessed the expression level of these ML-specific TFs in large
cohorts of breast cancer samples. Analysis of different data sets of
breast cancer patients25,39 showed that MYC overexpression anti-
correlated with ESR1 and GATA3 transcript levels (Supplemen-
tary Fig. 2h–j). Moreover, querying the proteome of genome-
associated TCGA tumor samples40 showed that the protein
abundance of both ESR1 and GATA3 decreased in those breast
cancers with augmented level of MYC (Fig. 1h). Together, these
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data indicate that MYC overexpression induced dedifferentiation
of luminal cells by downregulating the expression of lineage-
specific TFs, thereby supporting the reprogramming towards a
progenitor-like state (Fig. 1i).
Sustained MYC overexpression confers stem cell-like traits. On
the basis of the observed MYC-induced cell reprogramming, we
asked whether MYC overexpression could enrich for cells with
functional stem cell-like properties. We therefore measured the
ability of IMEC WT and -MYC to grow for subsequent passages
in low adherence conditions as mammospheres41. While WT cells
formed mammospheres with low efficiency and did not pro-
liferate beyond the second passage, cells overexpressing MYC
showed enhanced sphere formation efficiency (SFE) (Fig. 2a–c). A
similar increment in mammospheres formation was measured in
luminal breast cancer cell lines upon MYC overexpression
(Supplementary Fig. 3a, b). MYC sustained the propagation of
mammospheres for several passages, indicating acquisition of
long-term self-renewal capacity (Fig. 2b, c). Furthermore, IMEC-
MYC mammospheres showed enrichment for cells expressing
ALDH1, a distinctive marker of mammary stem cells42 (Fig. 2d).
Of importance the observed phenotype was a MYC-dependent
effect, as IMEC expressing other oncogenic hits showed reduced
long-term capacity to propagate as mammospheres (Supple-
mentary Fig. 3c–f). To quantify the relative enrichment for cells
endowed with self-renewing capacity, we performed single cell
clonogenic assay. The obtained result indicated that IMEC WT
could not give rise to any single cell-derived clone, while MYC
overexpression was associated with the highest clonogenic
potential (Fig. 2e). Moreover, single cell-derived primary spheres
(named M1) were further enriched in cells with self-renewing
capacity, showing higher SFE with respect to the parental het-
erogeneous population (Fig. 2f). Of importance, the measured
enrichment of SFE was not due to clonal selection as independent
single-cell isolated clones gave rise to similar increment in
mammospheres formation (Supplementary Fig. 3g). Accordingly,
knock-down of the exogenous MYC in mammospheres impaired
the measured clonogenic potential (Supplementary Fig. 3h, i).
Finally, we showed that under differentiation conditions, single
cell-derived mammospheres expressed luminal (CK8 and ER-α)
and myoepithelial (CK14 and α-SMA) markers, indicative of
enrichment for stem cell-like cells endowed with multipotency
(Fig. 2g).
To investigate whether MYC supported the activation of a stem
cell-like transcriptional program, we profiled gene expression of
single-cell-derived secondary mammospheres (clone M2 #1,
thereafter named M2), determining differentially expressed genes
with respect to IMEC-MYC (Fig. 2h). GO analyses showed that
mammospheres were characterized by further upregulation of
genes involved in metabolic pathways and downregulation of
genes involved in developmental processes (Fig. 2h, i), indicative
of reinforcement of MYC-driven transcriptional program.
Furthermore, M2 upregulated genes involved in Wnt and Hippo
signaling pathways, which are critical regulators of stem cell self-
renewing43,44 (Fig. 2h, i and Supplementary Fig. 3j). Notably,
GSEA analysis also revealed that the core embryonic stem cell-
like gene signature was over-represented in M2 with respect to
IMEC-MYC, and that genes codifying for MYC-related factors
(MYC Module) significantly contributed to this transcriptional
program (Fig. 2j and Supplementary Fig. 3k)45. Of note,
comparative analyses of gene expression profiling showed that
MYC induced a common transcriptional program among
independent single-cell-derived clones of mammospheres (M2
clones #2−4) (Supplementary Fig. 4a, b). Moreover, the retrieved
independent clones activated the same set of genes that were
induced in M2 clone with respect to IMEC-MYC, including the
embryonic stem cell-like gene signature (Supplementary Fig. 4c,
e). Importantly, long-term maintenance of mammospheres and
their subsequent sub-cloning was not supported by an increment
of the MYC protein level and genomic instability (Supplementary
Fig. 4f–h), thus arguing against clonal selection. Collectively, the
above data suggest that MYC overexpression in luminal cells
favor the onset of stem cell-like traits, such as sustained self-
renewing capacity and re-activation of a pluripotency-associated
transcriptional program (Fig. 2k).
MYC induces an alternative epigenetic program. To gain
insights into the mechanisms through which MYC induces cel-
lular reprogramming, we performed ChIP-seq analyses to profile
chromatin modifications and the binding of MYC in IMEC WT,
-MYC and mammospheres (Fig. 3). Considering that nearly 50%
of MYC binding sites localized at promoters (Fig. 3a), we ana-
lyzed the transcriptional effects of increasing the MYC levels on
these loci, in response to its overexpression. By ranking MYC-
bound genes on the basis of their gene expression pattern, we
defined two distinct subsets of targets whose expression aug-
mented or decreased in response to MYC association, respectively
(Fig. 3b and Supplementary Fig. 5a, b). Comparative analyses
between these two subsets showed that in the steady state (IMEC
WT) MYC occupancy was higher among the upregulated genes
and it further increased in response to MYC overexpression
(Fig. 3c and Supplementary Fig. 5c). Of note, the different MYC
occupancy correlated with a specific enrichment for canonical E-
box among the induced genes (Supplementary Fig. 5d), in
agreement with previous reports37,38. Importantly, by analyzing
previously published data sets37,38, we confirmed that these two
distinct subsets of MYC targets were induced and repressed
accordingly, upon MYC activation in other two independent cell
lines (Supplementary Fig. 5e, f). Considering that the transcrip-
tional response to MYC overexpression has been correlated with
the ratio between MYC and MIZ1 binding37, we quantified their
relative occupancy at the promoters of the two subsets (Supple-
mentary Fig. 5g-j). We showed that in both analyzed data sets the
downregulated genes had a lower MYC/MIZ1 ratio, supporting
the notion that these targets are directly repressed by MYC in
conjunction with MIZ1 binding, while high MYC/MIZ1 ratio
Fig. 3 MYC induces an alternative epigenetic program in mammary epithelial cells. a Barplot showing the distribution of MYC peaks on indicated genomic
features in IMEC WT, IMEC-MYC, and M2. b Heatmap showing the dynamic behavior of MYC normalized ChIP-seq signals on MYC-bound TSS.
Expression of annotated genes is reported. RPM reads per million. c Tag density plots of MYC normalized ChIP-seq signals in IMEC WT, IMEC-MYC, and
M2, centered on up- (left) and downregulated (right) TSS. RPM reads per million. d GO of up- (upper panel) and downregulated (lower panel) genes
bound by MYC on their TSS. e Identification of modulated enhancers among IMEC WT, IMEC-MYC, and M2. In the upper panel, the Venn diagram shows
the overlap of H3K4me1 ChIP-seq peaks among different cell types. In the lower panel, identified H3K4me1-positive regions were analyzed for their
enrichment in H3K27ac, leading to identification of modulated and unchanged enhancers in the reported comparisons. f Heatmap showing the dynamic
behavior of H3K4me1, H3K27ac, and MYC normalized ChIP-seq signals overidentified modulated enhancers. Expression of associated genes is reported.
Key relevant genes associated to different enhancers groups are indicated on the right. RPM reads per million. g TF binding motifs enrichment at enhancers
activated in IMEC WT. h GO of genes associated to differentially modulated enhancers in IMEC WT and M2
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characterizes the upregulated genes, indicating a direct MYC-
mediated transcriptional activation. Importantly, GO analyses
showed that these two subsets were enriched for genes belonging
to different functional categories (Fig. 3d). Supra-physiological
expression of MYC has been associated to invasion of almost all
active regulatory elements in the genome29,30,37,46. The specificity
of the differential binding affinity and its association with tran-
scription modulation was further supported by the ChIP-seq data
analyses showing that more than 18,000 active promoters marked
by H3K4me3 were not bound by MYC (Supplementary Fig. 6a).
These results indicated that in this biological context MYC
activation did not caused chromatin invasion of active regulatory
elements29,30,37,46. Together these analyses showed that MYC
occupancy on promoters determined the transcriptional out-
comes of MYC-target genes.
Considering that MYC also associated to introns and intergenic
regions (Fig. 3a), we investigated whether it occupied and
modulated the activation of enhancers. By profiling the distribu-
tion of H3K4me1 in IMEC WT, -MYC, and M2, we mapped all
the putative distal cis-regulatory elements (Fig. 3e, upper panel).
Thereafter, we defined the active enhancers by profiling the
relative enrichment for H3K27ac at these loci. Overall, the cellular
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reprogramming was mirrored by a highly dynamic modulation of
the defined cis-regulatory elements giving rise to different
enhancer states (Fig. 3e, lower panel). The comparative analyses
showed that a subset of enhancers were repressed in the MYC-
overexpressing cells as they showed a consistent reduction of the
H3K27ac level (Fig. 3f). Using a criterion of proximity to assign
each enhancer to its regulated gene47, we observed that enhancer
decommissioning determined the downregulation of their related
genes (Fig. 3f and Supplementary Fig. 6b). Among these genes we
identified TFs involved in establishing the transcriptional
regulatory network of luminal cells, such as TFAP2C, TBX3,
and ZNF217 (Fig. 3f and Supplementary Fig. 6c). In addition,
these repressed enhancers were enriched for binding sites of
luminal-specific TFs (Fig. 3g), in accordance with the down-
regulation of genes associated to ML-specific enhancers (Fig. 1e).
Of note, GO analyses highlighted that the WT-specific activated
enhancers were mainly related to genes involved in the integrin,
EGF and PI3K signaling pathways (Fig. 3h).
By focusing on the chromatin modulations occurring in the
mammospheres, we identified a subset of enhancers, which were
specifically activated in M2 (Fig. 3e and Supplementary Table 1).
These de novo enhancers were defined as distal genomic regions,
which did not carry H3K4me1 and H3K27ac in IMEC and gained
these histone modifications upon transition to a stem cell-like
state (Fig. 3f). In addition, the activation of de novo enhancers
was associated with an increment of MYC binding and with an
overall increased expression of the related genes (Fig. 3f and
Supplementary Fig. 6b, d, e). We found that stem cell-associated
TFs and genes involved in activating the Wnt signaling were
strongly enriched in this subset of enhancers (Fig. 3f–h). Taken
together, these results indicated that the MYC-induced alteration
of the luminal-specific transcriptional program associates with
the repression of those enhancers that modulate the expression of
the luminal lineage-specific TFs. In addition, the acquisition of a
stem cell-like fate is associated with the activation of de novo
enhancers that control the expression of TFs and signaling
pathways which are frequently activated in both somatic and
cancer stem cells5,48–51.
Activation of de novo enhancers drives oncogenic pathways.
We further characterized the de novo enhancer by ranking their
related genes according to their expression level in mammo-
spheres and we observed a positive correlation between over-
expressed genes and increased MYC recruitment at their
enhancers (Fig. 4a and Supplementary Fig. 7a). GO analyses
showed that the enhancer-dependent regulated genes were asso-
ciated with the modulation of Wnt pathways (Fig. 4b). Specifi-
cally, we identified genes coding for oncogenic TFs as well as
genes involved in regulating both the canonical and non-
canonical Wnt pathways, which are often deregulated in breast
cancer (Fig. 4c and Supplementary Fig. 7b, c)52–54. By defining
the set of genes whose de novo enhancers were bound by MYC
and induced in mammospheres, we showed that MYC associated
with one third of the 289 regulated genes (Fig. 4c and Supple-
mentary Fig. 7d). Of importance, the increment of expression of
this subset of genes correlated with augmented MYC occupancy
at the relative enhancers (Fig. 4d and Supplementary Fig. 7e, f). In
addition the knock-down of the exogenous MYC, which cause a
50% reduction of total MYC protein (Supplementary Fig. 3h),
impaired the transcriptional activation of its targets (Supple-
mentary Fig. 8a). Next, we investigated the direct contribution of
MYC binding to the chromatin state of the de novo enhancers by
measuring the relative enrichment for H3K4me1, H3K27ac, and
MYC at these loci (Fig. 4e). These analyses showed that the M2-
induced enhancers are characterized by a large distribution of
both H3K27 and K4me1 marks, spanning as average regions over
3.1 kb (Fig. 4e). Of note, the distribution of these histone marks is
similar to the pattern of the stretch- and super-enhancers which
compromise dense TFs binding sites, forming cluster of enhan-
cers that regulate the expression of lineage-specifying genes20,55.
In addition, on MYC-target de novo enhancers, we found that
MYC binding peaked at the center of the H3K27ac-enriched
region, suggesting a direct contribution to the deposition of this
active histone mark (Fig. 4e). Moreover, by performing motif
discovery analysis we found the highest enrichment for FOX- and
SOX-family members, as well as ETS1 motifs (Fig. 4f). Impor-
tantly, among the MYC-target de novo enhancers, we found a
specific enrichment for a non-canonical E-box29, indicating that
MYC association is mediated by its direct binding to the chro-
matin. In summary, these data strongly support the notion that
de novo enhancers modulate the transcriptional activation of
oncogenic pathways. In addition we characterized a subset of de
novo enhancers, which are enriched for MYC binding at their
epicenter, suggesting a modulatory function in their activation.
WNT pathway supports MYC-induced stem cell features. To
establish whether this enhancer-mediated regulation determined
the overall hyperactivation of the Wnt pathway in mammo-
spheres, we verified the transcriptional upregulation of Wnt
pathway-related genes, including the FZD1 and FZD8 receptors
and LRP6 co-receptor (Fig. 5a). In addition, the two major
inhibitors of the pathway, DKK1 and SFRP1, were strongly
downregulated in cells overexpressing MYC (Fig. 5a). Next, to
detect Wnt responsive cells, we transduced IMEC-MYC with a
lentiviral vector containing a 7xTCF-eGFP reporter cassette
(7TGP). FACS analyses showed that the Wnt pathway was acti-
vated in mammospheres and not in IMEC-MYC (Fig. 5b). In
order to determine whether WNT signaling activation could have
a functional role in MYC-induced stem cell features, we discerned
between IMEC-MYC with the highest (GFPhigh) and the lowest
(GFPlow) signal for Wnt pathway activation. Dye retention assay
showed that Wnt responsive cells (GFPhigh) were enriched for
Fig. 4 Activation of de novo enhancers drives oncogenic pathways. a On the left, heatmap showing the ranked differential expression profile of genes
associated to M2 de novo enhancers in M2 vs. IMEC-MYC. On the right, correlation plot between the fold change (FC) expression and differential MYC
binding in M2 vs. IMEC-MYC, on enhancers of induced genes in mammospheres. Each dot represents a bin of ten genes. b GO of genes associated to M2
de novo enhancers and transcriptionally induced in M2 vs IMEC-MYC. c Heatmap showing the dynamic behavior of MYC and H3K27ac normalized ChIP-
seq signals overidentified enhancer regions whose associated genes are transcriptionally induced in M2 with respect to IMEC-MYC with either increased
MYC binding in M2 or not. Expression of associated genes is reported. Relevant genes belonging to the two groups are indicated on the right. RPM reads
per million. d Notched boxplot showing the distribution of the fold change (FC) of the expression values between M2 spheres and IMEC-MYC of genes
associated to de novo enhancers differentially bound by MYC. Horizontal black lines indicate medians. Boxes extend from the first to third quartile and the
Tukey method was used to plot whiskers. (*P < 0.05; Student’s t-test). e Tag density plots of H3K4me1, H3K27ac, and MYC normalized ChIP-seq signals in
IMEC WT, IMEC-MYC, and M2, centered on enhancers regions associated to genes which are either only transcriptionally induced (left) or also enriched
for MYC binding (right) in M2 with respect to IMEC-MYC. f Tables depicting transcription factors binding motifs enrichment at the center (±2 kb) of
enhancers associated to genes which are either only transcriptionally induced (left) or also enriched for MYC binding (right) in M2 with respect to IMEC-
MYC
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slow-dividing cells, which retained higher level of the cell tracer,
suggesting enrichment for stem cells (Fig. 5c). Given the cellular
heterogeneity within the mammospheres population, we per-
formed single cell sorting of GFPhigh and GFPlow cells (Fig. 5d
and Supplementary Fig. 8c). On average, by analyzing indepen-
dent clones we determined that the GFPhigh sub-population
showed enrichment for cells with self-renewing capacity (Fig. 5e,
left panel). We further characterized the GFPhigh-derived primary
spheres (GFPhigh-derived M1) with respect to the relative
enrichment for Wnt pathway activation. The obtained results
showed a concomitant increment of Wnt signaling in GFPhigh-
derived with respect to the GFPlow-derived M1 cells (Fig. 5e, left
panel and Supplementary Fig. 8c). Furthermore, by performing
serial clonogenic assay of both GFPhigh and GFPlow cells derived
from independent clones, we observed that the Wnt responsive
population was further endowed with self-renewing capacity,
giving rise to clones characterized by enhanced activation of the
pathway (Fig. 5e, right panel and Supplementary Fig. 8c). Gene
expression profiling of sorted GFPhigh and GFPlow cells showed
that Wnt-responsive cells were enriched for a mammary stem cell
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transcriptional program and correlated with metastatic tran-
scriptional signatures (Fig. 5f, g). These results suggest a corre-
lation between the reactivation of Wnt pathway and acquisition
of a stem cell-like transcriptional program, which has been
associated with increased risk of developing recurrent
cancer42,56,57.
MYC-induced reprogramming favors the onset of TICs. To
determine whether MYC-induced reprogramming favors the
onset of TICs in vivo, we challenged IMEC-MYC with an addi-
tional oncogenic insult by overexpressing PIK3CAH1047R, which
caused hyper-activation of PI3K pathway (Supplementary
Fig. 9a). PIK3CAH1047R expression enhanced MYC-related phe-
notype and increased self-renewing capacity (Supplementary
Fig. 8b, c). In addition, IMEC-MYC-PIK3CAH1047R cells formed
about threefold more colonies in soft agar and showed migration
capacity (Supplementary Fig. 9d, e), suggesting that they were
enriched for transformed cells. To address this aspect, we injected
IMEC-MYC-PIK3CAH1047R cells and the corresponding controls
in the sub-renal capsule of immunocompromised mouse hosts.
No tumors arose when an equal number of IMEC WT, -MYC or
-PIK3CAH1047R were injected, which instead survived locally
giving rise to distinguishable mammary gland-like structures
(Fig. 6a). IHC analyses showed that transplantation of IMEC WT
into a permissive in vivo context, which favors growth and for-
mation of organized luminal-like structures58,59, permitted the
engraftment of these cells, maintaining features of luminal cells.
Of note, MYC overexpression caused decrement of luminal
markers CK8/18 and the downregulation of ER-α, thus recapi-
tulating the transcriptional repression measured in vitro. In
contrast, all mice injected with IMEC-MYC-PIK3CAH1047R cells
formed tumors composed by highly proliferative (KI67+) and
poorly dedifferentiated cells (Fig. 6a). By performing in vivo
limiting dilution assay, we estimated a frequency of TICs of 1/832
(Supplementary Fig. 9f), suggesting that IMEC-MYC-
PIK3CAH1047R were enriched for TICs. Of note, the obtained
results were not dependent on the site of injection, as orthotopic
xenograft transplantation assay gave similar results with IMEC-
MYC-PIK3CAH1047R forming highly proliferative and hetero-
geneous tumors expressing both luminal (CK8/18) and basal
(CK5/6 and p63) markers (Fig. 6b, c). In addition, tumors were
negative for ER-α and PR and did not show overexpression of
HER2 (Fig. 6c), recapitulating the histo-pathological features of
basal-like breast cancer. To determine long-term tumorigenic
potential, xenograft-derived (XD) cells obtained from primary
tumors were re-injected in the mammary gland of secondary
recipient mice. Serial transplantations showed that the XD cells
maintained tumorigenicity, forming tumors with features
resembling the primary one (Fig. 6d). Notably, XD cells showed
considerable migration and metastatic seeding capacity as, after
chirurgical resection of secondary tumors, all treated animals
developed macro-metastasis in liver, lung, and spleen (Fig. 6e).
Taken together, these results suggest that IMEC-MYC-
PIK3CAH1047R were endowed with long-term tumorigenic
capacity and metastatic potential.
MYC-driven oncogenic signature in basal-like breast cancer.
We next asked whether the MYC-dependent oncogenic signature,
activated in M2 by de novo enhancer modulation, could be
associated with IMEC-MYC-PIK3CAH1047R tumorigenicity. We
measured a significant transcriptional upregulation of these
oncogenes in both primary and secondary tumors, in respect to
parental cells (Fig. 7a and Supplementary Fig. 9g). Con-
comitantly, we determined activation of the respective enhancers
in XD cells, suggesting that the same molecular mechanism dri-
ven by MYC in M2 cells was responsible for their upregulation in
tumorigenic cells (Fig. 7b and Supplementary Fig. 9h). To assess
whether our findings are clinically relevant, we investigated the
expression of MYC-dependent oncogenic signature in a database
of breast cancer patients. The average expression of MYC-
induced oncogenes is strongly upregulated in basal-like breast
cancers and predictive of a worst prognosis for this specific
molecular subtype (Fig. 7c–e). Among the MYC targets, those
that were specifically overrepresented within the basal-like breast
cancers, which include modulators of kynurenine, prostaglandin,
and Wnt pathways, are frequently deregulated in human can-
cers60–62. The pathological relevance of the identified MYC sig-
nature was further corroborated by the observation that the
expression of these genes correlated with reduced metastatic-free
survival in patients affected by high-grade breast cancer (Sup-
plementary Fig. 9i). Taken together these data demonstrated that
MYC-modulated enhancers activate oncogenic pathways, which
are associated with basal-like breast cancer in patients with a poor
prognosis.
Discussion
In this work, we report the central role of MYC in initiating and
sustaining a stepwise cell reprogramming process of mammary
epithelial cells toward a stem cell-like condition, favoring tumor
initiation and progression. Specifically, we show that MYC
induces dedifferentiation toward a progenitor-like state achieved
through downregulation of lineage-specifying TFs, resulting in
decommissioning of luminal-specific enhancers. The oncogene-
triggered loss of cell identity favors the acquisition of stem cell
traits, which is mirrored by activation of de novo oncogenic
enhancers. Importantly, the herein deciphered epigenetic repro-
gramming supports tumorigenesis as the oncogenic enhancers are
reactivated in the transformed cell counterpart. We further show
that MYC directly binds to a subset of de novo enhancers, sug-
gesting that it participates in activating oncogenic pathways
Fig. 5 Reactivation of WNT pathway supports MYC-induced stem cell features. a qRT-PCR of WNT pathway-related genes on IMEC WT, IMEC-MYC, and
M2 clones #1 and #2, normalized on spike-in RNAs. Data are means ± SEM (n= 3) (*P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test). b FACS analysis
showing the GFP signal of IMEC-MYC-7TGP cultured in adhesion or as mammospheres. c On the left, phase contrast images showing IMEC-MYC-7TGP
cultured in low adhesion conditions. Scale bar, 100 µm. On the right, FACS analysis showing GFP signal and dye retention profile of IMEC-MYC-7TGP
cultured in low adhesion conditions. d Scheme representing GFPhigh and GFPlow cells sorting from IMEC-MYC-7TGP, which gave rise to GFPhigh- and
GFPlow-derived 1° Spheres (M1). GFPhigh-derived 1° Spheres underwent a second single-cell sorting of GFPhigh and GFPlow cells, which gave rise to GFPhigh-
and GFPlow-derived 2° Spheres (M2). Representative FACS analysis showing GFP signal and median fluorescence intensity (MFI) of sorted IMEC-MYC-
7TGP and GFPhigh-derived M1 clones are reported. e On the left, single-cell spheres formation efficiency (SFE) of GFPhigh and GFPlow cells sorted from
IMEC-MYC-7TGP, which gave rise to M1 clones. MFI of GFPhigh- and GFPlow-derived M1 clones is reported. On the right, single-cell SFE of GFPhigh and
GFPlow cells sorted from GFPhigh-derived M1, which gave rise to M2 clones. MFI of GFPhigh- and GFPlow-derived M2 clones is reported. Data are means ±
SEM (n= 4). f GSEA of mammary stem cells (MaSCs) gene signature in freshly sorted GFPhigh and GFPlow cells (n= 3). g GSEA of lung, bone, and brain
metastatic signatures in freshly sorted GFPhigh and GFPlow cells (n= 3)
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involved in the formation and maintenance of TICs. Overall, we
established a key role of MYC as tumor reprogramming factor by
guiding the acquisition of stem cell-like traits, thereby increasing
the likelihood of neoplastic transformation upon further onco-
genic insults.
In oncogenic setting, supraphyisiological activation of MYC
promotes tumorigenesis by conferring selective cell growth
advantage63. It has been proposed that high level of oncogenic
MYC elicits RNA amplification by inducing a widespread
increase of transcription elongation of the pre-existing active
genes. Further increment of MYC levels in advanced tumorigenic
cells determines chromatin invasion, which is characterized by
MYC association with almost all the active promoters and
enhancers64,29,46. However, the functional relevance of MYC
occupancy at distal cis-regulatory elements in supporting
tumorigenesis has not been fully elucidated. By investigating the
functional relevance of MYC binding to enhancers, we found that
MYC drives cellular reprogramming by inducing cell type-specific
enhancer decommissioning, combined with activation of onco-
genic enhancers. Specifically, we showed that the MYC-driven
transcriptional reprogramming is supported by repression of cis-
regulatory elements controlling the expression of LDTFs. The
finding that the master TFs GATA3 and ESR1 are repressed by
MYC could explain the measured inactivation of luminal-related
enhancers and the consequent downregulation of the luminal
transcriptional program. Of importance, the MYC-repressed TFs
are tumor suppressors whose downregulation is strongly asso-
ciated with poorly differentiated basal-like breast cancers. Con-
sidering that in the same subset of breast cancers MYC pathway is
frequently overactivated25, our results suggest a possible func-
tional link between transcriptional repression of these tumor
suppressors and MYC activation in establishing and maintaining
basal-like tumors. Further validation with primary luminal cells
within an in vivo setting would be required to confirm that MYC
overexpression causes transcriptional repression of GATA3 and
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ESR1, thus triggering the acquisition of a progenitor-like state
which could favor the formation of basal-like tumors.
The herein deciphered multistep reprogramming process
consisted of the re-activation of a stem cell-like transcriptional
program, mirrored by the establishment of a specific epigenetic
landscape. We provide evidence that activation of de novo
enhancers corresponds to increased expression of the associated
genes, which are particularly enriched for pro-self-renewing TFs,
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Fig. 7 MYC-induced activation of oncogenic pathways in TICs. a qRT-PCR of genes associated to MYC-bound M2 de novo enhancers in IMEC-MYC-
PIK3CAH1047R and 1° and 2° xenograft tumors cells, normalized on GAPDH. Data are means ± SEM (n= 3) (**P < 0.01, ***P < 0.001; Student’s t-test).
b ChIP-qPCR assessing H3K27ac and H3K4me1 deposition at the MYC-bound M2 de novo enhancer regions in IMEC-MYC-PIK3CAH1047R and XD cells.
Data are means ± SEM (n= 3). c Average gene expression values of MYC direct target signature in breast cancer samples of the meta-data set stratified
according to molecular subtype. Data are shown as mean ± standard error of the mean (SEM) (P < 0.0001; unpaired ttest). d Gene expression levels of
MYC direct target genes (upper heatmap) and of basal-specific enhancer associated genes (MYC un-bound; lower heatmap) in breast cancer samples of
the meta-data set stratified according to molecular subtype. e Kaplan−Meier analysis representing the probability of metastasis-free survival in 751 basal-
like breast cancer patients from the meta-data set stratified according to high or low MYC direct target signature score
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with established roles in tumorigenesis. Moreover, components of
both canonical and non-canonical Wnt signaling were being re-
activated at this cellular state and we further demonstrate that
Wnt activation represents a bona fide functional marker of MYC-
induced reprogramming in mammary epithelial cells. Of impor-
tance, we showed that the same oncogenic enhancers are re-
activated upon tumor initiation, causing overexpression of the
regulated genes in both primary and secondary tumors. These
findings suggest that combinatorial targeting of the hyper-
activated oncogenic pathways may represent a therapeutic
rationale to switch-off the MYC-dependent epigenetic repro-
gramming, hampering its tumor initiation capacity.
Since MYC is not able to bind closed chromatin, the activation
of de novo enhancers should be ascribed to the activity of pioneer
TFs that induce a wave of chromatin remodeling that would allow
MYC binding to open regions. Motif discovery analyses at
enhancers associated with MYC binding showed enrichment for
FOX- and SOX-family members, which have been previously
shown to act as pioneer TFs. Given these observations, it could be
interesting to verify whether FOXC1 and SOX9, which has been
demonstrated to play a central role as regulator of breast can-
cers65,66, could also act as pioneer factors in MYC-induced
oncogenic cell reprogramming. Considering that their expression
is modulated by the activation of the de novo enhancers, we argue
that a self-reinforcing transcriptional network could support
epigenetic reprogramming in TICs.
It has been suggested that oncogene-driven cell plasticity in
which, following an appropriate oncogenic insult, most cell in a
tissue has the potential to acquire stem cell-like properties, par-
ticipates in determining tumor heterogeneity5–7,10,11,67. We pro-
pose that resetting of the epigenetic landscape, which allows the
establishment of a stem cell-like transcriptional program and
predisposes cells to neoplastic transformation, should be therefore
considered a hallmark of tumor initiation. This epigenetic
remodeling can indeed cause a susceptible state, in which cells are
more prone to acquire genetic alterations, going through trans-
formation and tumor progression. With this work we identified
MYC as a key player in oncogenic reprogramming as it triggers
tumor initiation through the modulation of the epigenetic state of
enhancers, thereby perturbing cell identity.
Methods
Cell lines. All experiments were performed in the following cell lines and deri-
vatives: hTERT-immortalized human mammary epithelial cells (IMEC, a kind gift
from Dr. Micheal Cole), T47D, MCF7, and ZR751, retrieved from ATCC. These
cell lines were used as representative of transformed mammary luminal epithelial
cells. All cell lines were tested for mycoplasma contamination and resulted
negative.
Animal studies. Animal studies were performed under the institutional guidelines
of animal care committee, Italian Ministry of Health authorization (IACUC 373/
2015-PR). Tumorigenicity studies were performed by the injection of 2×106 cells
mixed 1:6 with Matrigel (BD Biosciences #354230) in 30 µl under the sub-renal
capsule of 5-week-old NOD/SCID mice from Charles River Laboratories. Mice
were killed after 4 weeks from injection. Limiting dilution experiments were per-
formed by injecting 2×105, 2×104, 2×103, and 2×102 cells mixed 1:3 with Matrigel
in 30 µl under the sub-renal capsule of NOD/SCID mice. Mice were killed after
12 weeks from injection. Serial transplantation experiments were performed by
orthotopical injection of 2×106 cells, suspended in 30 µl of 1:6 Matrigel, in the
mammary gland of 5-week-old NOD/SCID mice from Charles River Laboratories.
Mice were killed when tumors reached 2 × 2 cm size. Tumor length and width was
measured with electronic caliber and tumor size was calculated using the formula:
(smaller diameter)2 × larger diameter × π/6. For metastasis formation analysis,
secondary tumors were removed and mice and organs were subjected to bioima-
ging 4 weeks later. In order to allow in vivo tracking of tumor and metastasis
formation, cells were transduced with a lentiviral vector encoding for Luciferase
(pTween-Luc-NOeGFP) and animals were monitored after Luciferin (VivoGlo
Luciferin, Promega) injection by using the Photon IMAGER (Biospace Lab). Data
were analyzed with M3 Vision software. At the end of the experiments, mice were
killed according to IACUC guidelines and tumors and metastasis collected for
in vivo imaging, immunohistochemistry, RNA extraction, and cells isolation.
Plasmids. pMXs-c-Myc was a gift from Shinya Yamanaka (Addgene plasmid
#13375); pBABE-puro-RAS V12 was a gift from Bob Weinberg (Addgene plasmid
#1768); MSCV-p53DD-iGFP was a gift from Wechsel-Reya lab; PGK-
H2BmCherry was a gift from Mark Mercola (Addgene plasmid # 21217); PIK3-
CAH1047R was subcloned from pBabe-puro-HA-PIK3CAH1047R, a gift from Jean
Zhao (Addgene plasmid # 12524), into PGK-H2BmCherry; 7xTcf-eGFP//SV40-
PuroR (7TGP) was a gift from Roel Nusse (Addgene plasmid #24305); pTween-
Luc-NOeGFP was a gift from Stassi lab. Inducible IPTG-driven shRNAs for Myc
and constitutive shRNAs for Myz-1 were purchased from Sigma-Aldrich.
Cell culture. hTERT-immortalized human mammary epithelial cells (IMEC) and
XD cells were cultured at 37 °C and 5% CO2 in 1:1 DMEM/F-12 medium (gibco
#11320-074) supplemented with insulin (Clonetics, MEGM SingleQuots #CC-
4136), EGF (Clonetics, MEGM SingleQuots #CC-4136), bovine pituitary extract
(Clonetics, MEGM SingleQuots #CC-4136), hydrocortisone (Clonetics, MEGM
SingleQuots #CC-4136) and 100 ng/ml cholera toxin (Sigma #8052). IMEC-MYC,
IMEC-PIK3CAH1047R, IMEC-P53DD, and IMEC-RAS were generated by trans-
ducing IMEC with pMXs-c-Myc, PGK-PIK3CAH1047R, pBABE-puro-RAS V12,
and MSCV-p53DD-iGFP vector, respectively. IMEC-MYC-7TGP cells were gen-
erated by transduction of IMEC-MYC with 7TGP vector. T47D and MCF7 cells
were cultured at 37 °C and 5% CO2 in DMEM high glucose (Euroclone
#ECB7501L) supplemented with 10% fetal bovine serum (Euroclone #ECS0180L),
1 mM sodium pyruvate (Euroclone #ECM0542D) and 2 mM glutamine (Euroclone
#ECB3000D). ZR751 cells were cultured at 37 °C and 5% CO2 in RMPI Medium
1640 (gibco #31870-025) supplemented with 10% fetal bovine serum, 2 mM glu-
tamine and 1 mM sodium pyruvate. MCF7-MYC, T47D-MYC, and ZR751-MYC
were generated by transduction with pMXs-c-Myc.
Mammospheres culture and related assays. Mammospheres culture was per-
formed as previously described41. Briefly, single cells were plated in ultralow
attachment plates (Corning) at a density of 2×104 viable cells/ml in 1:1 DMEM/F-
12 medium supplemented with insulin (Clonetics, MEGM SingleQuots #CC-4136),
EGF (Clonetics, MEGM SingleQuots #CC-4136), hydrocortisone (Clonetics,
MEGM SingleQuots #CC-4136), B-27 Supplement (Gibco # 17504044), 20 ng/ml
human FGF-basic (PeproTech #100-18B) and 5 μg/ml heparin (Sigma-Aldrich
#H3149). Formed mammospheres were collected after 6 days. For long-term clo-
nogenic assays, cells were transduced with PGK-H2BmCherry and single cells were
plated in 96-well plates, in six technical replicates, at a density of 4×103 viable cells
in 100 μl. After 6 days, fluorescence images of the entire wells were acquired. Then
the cells were collected and passed in the same condition. This was repeated for
four subsequent passages. Images were acquired with an Eclipse Ti fully automated
system (Nikon); spheres formation efficiency (SFE) and mammospheres area (μm2)
were measured using the NIS Element software (Nikon). Objects with an area
<2000 μm2 (diameter < 50 μm) were excluded from the analysis. Single-cell clo-
nogenic assay was performed in 96-well plates, in at least three biological replicates.
Single cells were sorted with a BD FACS Aria III sorter (BD Biosciences), one cell/
well and formed mammospheres were counted after 3 weeks by microscope
observation (time window required for primary spheres formation).
Immunofluorescence. For mammospheres differentiation assay, cells were grown
in mammospheres culture conditions for 6 days, then mammospheres were col-
lected and left lay down on collagen I-coated glass coverslips, in mammospheres
medium supplemented with 10% FBS. After 7 days mammospheres were fixed for
20 min at room temperature with 4% paraformaldehyde (Sigma-Aldrich #158127).
Coverslips were processed for immunofluorescence according to the following
conditions: permeabilization and blocking with PBS/1% BSA/0.3% Triton X-100
(blocking solution) for 1 h at room temperature, followed by incubation with
primary antibody (diluted in the blocking solution) for 2 h at RT, three washes in
the blocking solution and incubation with secondary antibodies (diluted in the
blocking solution) for 30 min at room temperature.
Images were acquired using a Leica TCS SP5 confocal microscope with HCX PL
APO ×63/1.40 objective. Confocal z stacks were acquired with sections of 0.35 μm.
In cases where image analysis was performed, image acquisition settings were kept
constant.
Primary antibodies are as follows: CK8 (Covance #1E8-MMS-162P), CK14
(Covance #AF64-155P), ER-α (Merk Millipore #F3-A 04-1564), α-SMA (abcam
#ab5694). Cell nuclei were visualized with DAPI (Sigma). Secondary antibodies
were goat-anti-mouse or -rabbit coupled to Alexa-488 or -568 (Invitrogen).
Flow cytometry analysis (FACS). ALDH activity was assessed with the Aldefluor
kit (Stemcell Technologies #1700) on IMEC WT and IMEC-MYC cultured as
mammospheres for one passage.
Dye retention assay was performed with CellTrace Violet Cell Proliferation Kit
(molecular probes #C34557) on IMEC-MYC-7TGP cultured as mammospheres for
one passage. After the staining, cells were re-plated in the same conditions and
acquired to FACS after 6 days.
Tumor digests. Tumors were chopped into small pieces in sterile conditions, then
incubated at 37 °C for 2 h in DMEM/F12 containing 2% bovine serum albumin,
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300 U/ml collagenase III (Worthington #M3D14157) and 100 U/ml hyaluronidase
(Worthington #P2E13472). Following digestion, tumor cell suspensions were pel-
leted and then suspended in 0.25% trypsin for 2 min.
Immunohistochemical analysis. Immunohistochemical analyses were carried out
on 5-µm-thick paraffin-embedded sections of breast cancer xenografts. Tissues
underwent antigen retrieval, where required permeabilized with cold 0.1% Triton X
100, and stained overnight at 4 °C with antibodies against Ki67 (MIB 1, Dako), p63
(4A4, Santa Cruz), CK5 (XM26, Novocastra), CK 5/6 (D5/16B4, Dako), CK8/18
(5D3, Novocastra), Vimentin (R28), PR (16, Biocare Medical), Her2 (D8F12, CST),
and ER (6F11, Novocastra). Successively, sections were incubated with biotinylated
secondary antibodies and exposed to streptavidin-peroxidase (Dako). Stainings
were revealed with 3-amino-9-ethylcarbazole substrate (AEC, Dako) and nuclei
counterstained with aqueous hematoxylin. For H/E, tissues were stained with
hematoxylin for 2 min and subsequently with eosin for 1 min.
Soft agar assay. Colony-forming assay was carried out using Noble agar (Sigma-
Aldrich #A5431). For the lower layer, agar was mixed with IMEC medium,
reaching a final concentration of 0.6% and plated on six-well plates. 4×105 cells
were plated on top of it, in 0.3% agar. Colony formation was monitored up to
21 days by microscope observation.
Invasion assay. 2×103 cells were plated in medium without growing factors and
placed onto Matrigel-coated (BD Biosciences #354230) transwells of 8-µm pore size
(Corning #3422). In the lower part of the transwell DMEM supplemented with
10% AB human serum (Euroclone, ECS0219D) was placed as a chemo-attractant.
The number of migrated cells in the lower chamber was calculated up to 72 h by
microscope observation.
Protein extraction and western blot analysis. Total protein extracts were
obtained as follows. Cells were washed twice with cold PBS, harvested by scrapping
in 1 ml cold PBS and centrifuged for 5 min at 1500 rpm. Harvested cell pellets were
lysed by the addition of 5× v/v ice-cold F-buffer 30 min at 4 °C. The chromosomal
binding proteins were then separated using BioRuptor waterbath sonicator
(Diagenode) at low setting for 5 min. Samples were sonicated in pulse of 30 s with
30 s intervals. Lysates were cleared by centrifugation for 10 min at 14,000 rpm at 4 °
C and supernatant was collected on ice. Protein concentration of lysates was
determined using PierceTM BCA Protein Assay Kit 24 (Thermo Scientific, 574
#23227), according to the manufacturer’s instructions. The absorbance was mea-
sured at λ= 595 using SAFAS spectrophotometer (SAFAS, Monaco). Values were
compared to a standard curve obtained from the BSA dilution series.
For western blots analysis, 20 μg of protein samples were boiled and loaded onto
a pre-cast Bolt 4−12% Bis-Tris Plus gels (Novex #NW04122BOX) and run in Bolt
MES running buffer (Novex #B0002). After electrophoresis, proteins were
transferred to a nitrocellulose membrane. Membranes were blocked in PBS-T
containing 5% Blotting-Grade Blocker (BIO-RAD #170-6404) (blocking buffer), for
1 h at RT with constant agitation and incubated with indicated primary antibody
O/N at 4 °C with agitation. The membrane was then washed three times with PBS-
T, each time for 5 min, followed by incubation with secondary antibody HRP-
conjugated for 1 h at RT. ECL reagents (GE Healthcare #RPN2232) was used to
initiate the chemiluminescence of HRP. The chemiluminescent signal was captured
using LAS3000 system (GE Healthcare).
Primary antibodies used are as follows: β-Actin (Sigma-Aldrich #A5441), c-Myc
(Cell Signaling #5605). Relative optical density was quantified with ImageJ
Software. Uncropped images of all the western blots are reported in Supplementary
Fig. 10.
RNA extraction, expression level quantification and microarray experiments.
Total RNAs were extracted from log-phase cells with TRIzol (Ambion #15596018),
according to the manufacturer’s instructions. Quantitative real-time PCR analysis
was performed with SuperScript III One-Step SYBR Green kit (Invitrogen #11746).
Relative gene expression levels were determined using comparative Ct method,
normalizing data on endogenous GAPDH or ERCC RNA Spike-In Mix (Ambion
#4456704). Primers used in this study are listed in Supplementary Table 4.
For microarray experiments, 500 ng of each sample of RNA were processed to
generate labeled cRNAs following the Illumina TotalPrep RNA amplification Kit
(Ambion #AMIL1791) protocol. cRNA concentration was quantified and subjected
to quality control on Agilent Bioanalyzer (Agilent Technologies #554 G2943CA)
and hybridized to HumanHT-12 v4 BeadChip Arrays (Illumina #15011977).
Microarray analysis. BeadChip Arrays were scanned with HiScan Array Scanner
(Illumina) using the iScan Control Software (Illumina). Genes and probes tran-
script levels were obtained from Illumina Intensity Data (.idat) files, applying
quantile normalization and background subtraction implemented by the Geno-
meStudio Gene Expression Module v1.0 Software (Illumina). All experiments in
each condition reported were performed on triplicate biological samples. Signals
associated with a p-value > 0.05 in all samples were discarded from the analysis.
Cut-off for up- and downregulation of gene expression was set to twofold change
threshold in all the analyses performed.
Computational analysis of gene expression data. Scatter plots, correlation
heatmaps and PCA analysis of gene expression data were performed in R (http://
www.R-project.org/). Differentially expressed genes were checked for biological
and functional enrichment using the GO-based online tool PANTHER Classifi-
cation System. Geneset Enrichement Analysis (GSEA) was performed with genesets
retrieved from both public available databases and indicated papers (Supplemen-
tary Data 1).
Chromatin immunoprecipitation (ChIP) assay. Each ChIP experiment was
performed in at least three independent biological samples. Briefly, cells were
crosslinked with 1% formaldehyde for 10 min at RT and the reaction was quenched
by glycine at a final concentration of 0.125 M, for 5 min at RT. Cells were lysed in
lysis buffer (50 mMTris-HCl pH 8, 0.1% SDS, 10 mM EDTA pH 8, 1 mM phe-
nylmethyl sulphonyl fluoride (PMSF, Sigma # P7626), protease inhibitor cocktail
(Roche #04693159001)) and chromatin was sonicated to an average size of 0.1–0.5
kb, using a Branson D250 sonifier (four cycles of 30 s, 20% amplitude). Fifty
micrograms of each sonicated chromatin was incubated O/N at 4 °C with 4 µg of
indicated antibodies (anti-MYC sc-764 Santa Cruz Biotechnology; anti-trimethyl
histone H3 Lys4 07-473 Millipore; anti-monomethyl histone H3 Lys4 8895 Abcam;
anti-acethyl histone H3 Lys27 4729 Abcam; anti-MIZ-1 10E237,38). Protein G-
coupled Dynabeads (Thermo Fisher Scientific # 10004D) were blocked O/N at 4 °C
with 1 mg/ml sonicated salmon sperm DNA (Thermo Fisher Scientific #AM9680)
and 1 mg/ml−1 BSA. Subsequently, blocked protein G-coupled Dynabeads were
added to the ChIP reactions and incubated for 4 h at 4 °C. Dynabeads linked to
ChIP reactions were then recovered and resuspended in RIPA buffer (10 mM Tris-
HCl, pH 8, 0.1% SDS, 1 mM EDTA, pH 8, 140 mM NaCl, 1% DOC, 1% Triton, 1 mM
PMSF, protease inhibitor cocktail). Magnetic beads were sequentially washed five
times with ice-cold RIPA buffer, twice with ice-cold RIPA-500 buffer (10 mM Tris-
HCl, pH 8, 0.1% SDS, 1 mM EDTA, pH 8, 500 mM NaCl, 1% DOC, 1% Triton, 1 mM
PMSF, protease inhibitor cocktail), twice with ice-cold LiCl buffer (10 mM Tris-
HCl, pH 8, 0.1% SDS, 1 mM EDTA, pH 8, 250 mM LiCl, 0.5% DOC, 0.5% NP-40, 1
mM PMSF, protease inhibitor cocktail) and once with TE buffer (10 mM Tris-HCl,
pH 8, 1 mM EDTA, pH 8, 1 mM PMSF, protease inhibitor cocktail). Crosslinking
was then reversed in direct elution buffer (10 mM Tris-HCl, pH 8, 0.5% SDS, 5 mM
EDTA, pH 8, 300 mM NaCl) at 65 °C O/N. Finally, DNA was purified using
Agencourt AMPure XP SPRI beads (Beckman #A63882), washed twice in EtOH
70% and dissolved in 60 ml of Tris-HCl, pH 8.0. DNA was analyzed by quantitative
real-time PCR using SYBR GreenER master mix (Thermo Fisher Scientific #
11762500). All experimental values were shown as percentage of input. To take into
account background signals, we subtracted the values obtained with a non-immune
serum to the relative ChIP signals (anti-mouse IgG CS200621 Millipore).
Antibodies. All the antibodies used in this study and the working dilutions for all
the experimental settings are reported in Supplementary Table 5.
ChIP-seq library generation and data analysis. Five nanograms of immuno-
precipitated and purified DNA was used to generate ChIP-seq libraries. Briefly, end
repair of DNA fragments was achieved by sequential 15 min incubations at 12 °C
and 25 °C with 0.15 U/μl T4 PNK (NEB #M0201L), 0.04 U/μl T4 POL (NEB
#M0203L) and 0.1 mM dNTPs (NEB #N0446S). A-base addition was performed by
incubating end-repaired DNA fragments with 0.25 U/μl of Klenow fragment (NEB
# M0212L) and 167 μM dATP (NEB N0440S) for 30 min at 30 °C. Adaptor ligation
was achieved by using the Quick ligation kit (NEB #M2200L) and performing an
incubation of 15 min at 25 °C. Processed DNA fragments were finally amplified
with a thermal cycler for 14 cycles, by using the PfuUltra II Fusion HS DNA Pol kit
(Agilent #600674). All DNA purification steps between the different enzymatic
reactions were performed using Agencourt AMPure XP SPRI beads (Beckman
#A63882). The obtained libraries were subjected to quality control on Agilent
Bioanalyzer (Agilent Technologies #G2943CA) before sequencing them with Illu-
mina HiSeq2000. Sequenced reads were aligned to the human genome (GRCh37/
hg19) by using Bowtie2 version 2.2.3 and only uniquely mapped reads were used in
the subsequent analyses. In order to find the regions of ChIP-seq enrichment over
background, we used different peak callers. For MYC ChIP-seq we used MACS2
(p-value < 1×10−6), while for histone modifications we used SICER V1.1 (window
size= 200; gap size= 200; FDR < 0.01). The HOMER software command “get-
DifferentialPeaks” was used to find ChIP-seq differentially enriched regions
between different IMEC samples (cut-offs= twofold change and p-value 1×10−4).
The HOMER software command “annotatePeaks.pl” was used to assign peaks and
enhancer regions to the nearest genes, according to GRCh37/hg19 annotation, and
to count the number of tags from different sequencing experiments on those
regions. Tag counts were then used to produce heatmaps with TM4 MeV
v4.9 software. Annotated genes were checked for biological and functional
enrichment using both the GO-based online tool PANTHER and GSEA, with
genesets retrieved from both publicly available databases and indicated papers.
Venn diagrams were generated using the online tool. Tag density plots around the
center of enhancers regions were quantified with the ngsplot 2.47 command ngs.
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plot.r and plotted with GraphPad Prism (GraphPad Software, San Diego, Cali-
fornia, USA, www.graphpad.com). Normalized BigWig tracks of ChIP-seq
experiments were generated with bedtools 2.24.0 and the bedGraphToBigWig
program and visualized in the UCSC Genome Browser. Motifs enrichment analysis
was performed with the online tool Analysis of Motif Enrichment (AME) of the
MEME suite v4.11.2 and with the HOMER command “findMotifsGenome.pl”. In
all the analyses reported data are normalized by per million mapped reads (RPM).
For Miz-1 global binding analysis (Supplementary Fig. 5e-j), data were retrieved
from GEO: GSE4467237 and GSE5914638. ChIP-seq data were mapped to human
genome (GRCh37/hg19) by using Bowtie2 and the HOMER software and ngsplot
2.47 were used to count normalized reads to generate box-plots and tag density
plots, respectively. For transcriptional profile analysis, normalized data from
microarray experiments were directly retrieved from GSE5914538, while RNA-seq
data retrieved from GSE4467237 were aligned to human genome (GRCh37/hg19)
by using Bowtie2 and normalized read counts were obtained by using the htseq-
count tool from HTSeq and DESeq2.
Collection and processing of breast cancer gene expression data. Breast cancer
gene expression data have been obtained from a collection of 4640 samples from 27
major data sets comprising microarray data of breast tumors annotated with
pathological information and clinical outcome (Supplementary Table 2). All data
were measured on Affymetrix arrays and have been downloaded from NCBI Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and EMBL-EBI
ArrayExpress (http://www.ebi.ac.uk/ arrayexpress/). Prior to analysis, all data sets
have been re-organized as described in ref. 68. Since raw data (.CEL files) were
available for all samples, integration, normalization, and quantification of gene
expression levels have been obtained with the procedure described in ref. 69. The
type and content of pathological and clinical annotations have been standardized,
among the various data sets, as described in ref. 49. This resulted in a compendium
(meta-data set) comprising 3661 unique samples from 25 independent cohorts
(Supplementary Table 3). Breast cancer data of the METABRIC collection, com-
prising microarray gene expression profiles and clinical annotations for 997 cancer
samples, were downloaded from the European Genome-Phenome Archive (EGA,
http://www.ebi. ac.uk/ega/) under accession number EGAD0001000021039. Ori-
ginal Illumina probe identifiers were mapped to Entrez gene IDs using the Bio-
conductor illuminaHumanv3.db annotation package for Illumina HT-12 v3 arrays
obtaining log2 intensity values for a total of 19,761 genes. The 522 primary tumors
of the TCGA breast cancer data set (The Cancer Genome Atlas Network, 2012)
were downloaded from the Comprehensive molecular portraits of human breast
tumors portal (Level 3 data arcive; https://tcga-data.nci.nih.gov/docs/publications/
brca_2012/).
Breast cancer molecular subtypes have been assigned using the PAM50 intrinsic
subtype classifier, i.e., the intrinsic.cluster.predict function, of the genefu R package.
Gene expression heatmaps have been generated using the function heatmap.2 of R
gplots package after row-wise standardization of the expression values. Average
signature expression has been calculated as the standardized average expression of
all signature genes in sample subgroups (e.g., molecular subtypes). The values
shown in graphs are thus adimensional. Signature scores have been obtained
summarizing the standardized expression levels of signature genes into a combined
score with zero mean70. All gene expression analyses were performed in R (version
3.2.0).
Survival analysis. To identify two groups of tumors with either high or low MYC
direct target signature, we used the classifier described in ref. 70, that is, a classi-
fication rule based on the MYC direct target signature score. Briefly, tumors were
classified as MYC direct target signature Low if the signature score was negative
and as MYC direct target signature High if the signature score was positive. To
evaluate the prognostic value of the signature, we estimated, using the
Kaplan–Meier method, the probabilities that patients would remain free of
metastasis. The Kaplan–Meier curves were compared using the log-rank
(Mantel–Cox) test. p-values were calculated according to the standard normal
asymptotic distribution. Survival analysis was performed in GraphPad Prism.
Quantification and statistical analysis. Statistical parameters are reported in
figure legends and include: number of replicates analyzed (n), dispersion and
precision measures (mean ± SEM) and statistical significance (p-value). Data have
been statistically assessed by one-tailed Student’s t-test and indicated in figure
legends. In figures, asterisks mean *p < 0.05, **p < 0.01, ***p < 0.001, ns= not sig-
nificant. p < 0.05 and lower were considered significant. All experiments were
performed in at least triplicate biological replicates. For microarray analysis,
transcript levels were quantile normalized and background subtracted using the
GenomeStudio Gene Expression Module v1.0 Software (Illumina). Signals asso-
ciated with a p-value > 0.05 in all samples were discarded from further analysis and
gene expression values <1 were set to 1. The threshold to define up- and down-
regulated genes was set to twofold changes. For ChIP-seq analysis the following
statistical parameters were used: MACS2 peak calling of MYC ChIP-seq (p-value <
1×10−6); SICER V1.1 peak calling of histone modification (FDR < 0.01); HOMER
“getDifferentialPeaks” (cut-offs= twofold change and p-value < 1×10−4). All ChIP-
seq data are normalized by library depth and reported as per million mapped reads
(RPM). Statistical p-value of GO, GSEA and AME are reported in figures. Data
collection and analyses of all studies involving animals were conducted randomly
and not blinding.
Data availability. Data resources: Raw and quantile normalized data files for the
microarray analysis have been deposited in the NCBI Gene Expression Omnibus
under accession number GSE86407.
Raw data and genomic regions of ChIP-seq peaks have been deposited in the
NCBI Gene Expression Omnibus under accession number GSE86412.
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